Literature DB >> 26101059

Sustained wash-resistant receptor activation responses of GPR119 agonists.

J Daniel Hothersall1, Charlotte E Bussey2, Alastair J Brown3, James S Scott2, Ian Dale4, Philip Rawlins4.   

Abstract

G protein-coupled receptor 119 (GPR119) is involved in regulating metabolic homoeostasis, with GPR119 agonists targeted for the treatment of type-2 diabetes and obesity. Using the endogenous agonist oleoylethanolamide and a number of small molecule synthetic agonists we have investigated the temporal dynamics of receptor signalling. Using both a dynamic luminescence biosensor-based assay and an endpoint cAMP accumulation assay we show that agonist-driven desensitization is not a major regulatory mechanism for GPR119 despite robust activation responses, regardless of the agonist used. Temporal analysis of the cAMP responses demonstrated sustained signalling resistant to washout for some, but not all of the agonists tested. Further analysis indicated that the sustained effects of one synthetic agonist AR-231,453 were consistent with a role for slow dissociation kinetics. In contrast, the sustained responses to MBX-2982 and AZ1 appeared to involve membrane deposition. We also detect wash-resistant responses to AR-231,453 at the level of physiologically relevant responses in an endogenous expression system (GLP-1 secretion in GLUTag cells). In conclusion, our findings indicate that in a recombinant expression system GPR119 activation is sustained, with little evidence of pronounced receptor desensitization, and for some ligands persistent agonist responses continue despite removal of excess agonist. This provides novel understanding of the temporal responses profiles of potential drug candidates targetting GPR119, and highlights the importance of carefully examining the the mechanisms through which GPCRs generate sustained responses.
Copyright © 2015 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AR-231,453 (PubChem CID: 47069); ARN-II (PubChem CID: 16036825); AZ1 (PubChem CID: 51030901); AZ2 (PubChem CID: 51029876); AZ3 (PubChem CID: 56643412); Agonist; Binding kinetics; Desensitization; GPR119; GSK-1292263 (PubChem CID: 24996872); MBX-2982 (PubChem CID: 25025505); Membrane deposition; Sustained signalling; oleoylethanolamine (PubChem CID: 2583454)

Mesh:

Substances:

Year:  2015        PMID: 26101059     DOI: 10.1016/j.ejphar.2015.06.031

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

Review 1.  When trafficking and signaling mix: How subcellular location shapes G protein-coupled receptor activation of heterotrimeric G proteins.

Authors:  Braden T Lobingier; Mark von Zastrow
Journal:  Traffic       Date:  2019-02       Impact factor: 6.215

2.  Structural identification of lysophosphatidylcholines as activating ligands for orphan receptor GPR119.

Authors:  Peiyu Xu; Sijie Huang; Shimeng Guo; Ying Yun; Xi Cheng; Xinheng He; Pengjun Cai; Yuan Lan; Hu Zhou; Hualiang Jiang; Yi Jiang; Xin Xie; H Eric Xu
Journal:  Nat Struct Mol Biol       Date:  2022-08-15       Impact factor: 18.361

3.  Structure-Activity Relationships of the Sustained Effects of Adenosine A2A Receptor Agonists Driven by Slow Dissociation Kinetics.

Authors:  J Daniel Hothersall; Dong Guo; Sunil Sarda; Robert J Sheppard; Hongming Chen; Wesley Keur; Michael J Waring; Adriaan P IJzerman; Stephen J Hill; Ian L Dale; Philip B Rawlins
Journal:  Mol Pharmacol       Date:  2016-11-01       Impact factor: 4.436

4.  YH18968, a Novel 1,2,4-Triazolone G-Protein Coupled Receptor 119 Agonist for the Treatment of Type 2 Diabetes Mellitus.

Authors:  Taedong Han; Byoung Moon Lee; Yoo Hoi Park; Dong Hoon Lee; Hyun Ho Choi; Taehoon Lee; Hakwon Kim
Journal:  Biomol Ther (Seoul)       Date:  2018-03-01       Impact factor: 4.634

5.  Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Suppress Voluntary Alcohol Intake in Male Wistar Rats.

Authors:  Vincent N Marty; Mehdi Farokhnia; Joseph J Munier; Yatendra Mulpuri; Lorenzo Leggio; Igor Spigelman
Journal:  Front Neurosci       Date:  2020-12-23       Impact factor: 4.677

Review 6.  Targeting the GPR119/incretin axis: a promising new therapy for metabolic-associated fatty liver disease.

Authors:  Jianan Zhao; Yu Zhao; Yiyang Hu; Jinghua Peng
Journal:  Cell Mol Biol Lett       Date:  2021-07-07       Impact factor: 5.787

7.  Chemistry and Hypoglycemic Activity of GPR119 Agonist ZB-16.

Authors:  Ivan N Tyurenkov; Denis V Kurkin; Dmitry A Bakulin; Elena V Volotova; Evgeny I Morkovin; Mikhail A Chafeev; Ruben N Karapetian
Journal:  Front Endocrinol (Lausanne)       Date:  2018-09-19       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.